Stockscreener 앱 받기
383.89
0.21%
0.79
시간 외 거래:
383.89
전일 마감가:
$383.10
열려 있는:
$385.42
하루 거래량:
709.00K
Relative Volume:
0.46
시가총액:
$146.23B
수익:
$23.22B
순이익/손실:
$2.86B
주가수익비율:
51.88
EPS:
7.4
순현금흐름:
$3.58B
1주 성능:
+0.33%
1개월 성능:
+1.69%
6개월 성능:
-0.29%
1년 성능:
+9.80%
1일 변동 폭
$382.80
$388.69
1주일 범위
$375.55
$388.69
52주 변동 폭
$314.93
$406.19
스트라이커 Stock (SYK) Company Profile
명칭
Stryker Corp
전화
(269) 385-2600
주소
1941 STRYKER WAY, PORTAGE, MI
SYK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYK
Stryker Corp
|
383.89 | 146.23B | 23.22B | 2.86B | 3.58B | 7.40 |
|
ABT
Abbott Laboratories
|
133.58 | 232.41B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.09 | 155.73B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
87.44 | 106.37B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.52 | 45.88B | 5.54B | 4.18B | 623.10M | 7.00 |
스트라이커 Stock (SYK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 재개 | Citigroup | Buy |
| 2024-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-10 | 개시 | Wolfe Research | Outperform |
| 2024-05-30 | 개시 | Goldman | Neutral |
| 2024-05-22 | 업그레이드 | Needham | Hold → Buy |
| 2024-01-31 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-10-20 | 개시 | ROTH MKM | Buy |
| 2023-09-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-03-29 | 개시 | UBS | Neutral |
| 2023-01-25 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2023-01-09 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-11-01 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-28 | 업그레이드 | Edward Jones | Hold → Buy |
| 2022-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2022-07-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-13 | 개시 | Truist | Hold |
| 2022-03-16 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-03-15 | 재개 | Evercore ISI | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-12-10 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-12-07 | 개시 | Loop Capital | Buy |
| 2021-09-14 | 재개 | Raymond James | Mkt Perform |
| 2021-07-28 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-06-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-05-25 | 개시 | Barclays | Underweight |
| 2020-10-06 | 개시 | Northland Capital | Market Perform |
| 2020-09-11 | 개시 | Wolfe Research | Peer Perform |
| 2020-04-13 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2020-04-01 | 다운그레이드 | Goldman | Buy → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Buy |
| 2020-01-08 | 개시 | SunTrust | Hold |
| 2020-01-07 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2020-01-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-12-30 | 재확인 | BTIG Research | Buy |
| 2019-11-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-30 | 재확인 | BofA/Merrill | Buy |
| 2019-07-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-01-30 | 재확인 | Canaccord Genuity | Buy |
| 2019-01-03 | 개시 | Deutsche Bank | Buy |
| 2019-01-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-08-16 | 개시 | BTIG Research | Buy |
| 2018-06-27 | 개시 | Bernstein | Mkt Perform |
| 2018-04-27 | 재확인 | Stifel | Buy |
모두보기
스트라이커 주식(SYK)의 최신 뉴스
The Zacks Analyst Blog Highlights Mastercard, Verizon Communications, Stryker, Espey Mfg. & Electronics and Comstock Holding - Yahoo Finance
Top Analyst Reports for Mastercard, Verizon & Stryker - MSN
Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Surgical Booms Market Is Booming WorldwideStryker - openPR.com
Is Stryker Stock Underperforming the Nasdaq? - MSN
Is Stryker Stock Underperforming The Nasdaq? - Barchart.com
Pressure Relief Devises Industry Overview: Innovations & Key - openPR.com
Barclays maintains Stryker stock Overweight rating, $443 target By Investing.com - Investing.com South Africa
Barclays maintains Stryker stock Overweight rating, $443 target - Investing.com
Stryker's Profits Outshine Forecasts Thanks To Device Demand - Finimize
Here's How Much $1000 Invested In Stryker 20 Years Ago Would Be Worth Today - Benzinga
Stryker tops list of West Michigan’s largest publicly traded companies - Crain's Grand Rapids Business
Jim Cramer on Stryker Corporation (SYK): “I Don’t Like It Enough” - Insider Monkey
Jim Cramer Had These 21 Stocks on His Radar - Insider Monkey
Stryker’s SWOT analysis: stock poised for growth amid strategic moves - Investing.com
Stryker corp VP sells shares worth $211,369 - Investing.com Australia
Stryker corp’s chief accounting officer sells $211,369 in shares By Investing.com - Investing.com South Africa
Stryker corp VP sells shares worth $211,369 By Investing.com - Investing.com Nigeria
Stryker corp’s chief accounting officer sells $211,369 in shares - Investing.com Australia
Stryker Hits Treace With Patent Suit Over Surgical Foot-Implants - Bloomberg Law News
Stryker Corporation: Is Its Tuck-in Acquisition Strategy to Ensure Market Leadership In The Med-Tech Landscape? - Smartkarma
Citigroup Raises Price Target for Stryker (SYK) to $455 | SYK Stock News - GuruFocus
Stryker wins FDA clearance for minimally invasive back pain treatment - Yahoo Finance
Stryker (SYK) Price Target Raised by Citi to $455 | SYK Stock Ne - GuruFocus
Stryker (NYSE:SYK) Expands Pain Therapy With FDA Clearance For OptaBlate BVN System - Yahoo Finance
USITC to investigate Fiagon after Stryker medical device infringement claims - MLex
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System - Yahoo Finance
Stryker Receives FDA Clearance For OptaBlate System Aimed At Low Back Pain Relief: Retail’s Yet To React - Investing.com India
Stryker (SYK) Gains FDA Clearance for OptaBlate System - GuruFocus
Stryker (SYK) Secures FDA Clearance for OptaBlate Nerve Ablation System | SYK Stock News - GuruFocus
Stryker’s new system aims at chronic back pain relief - Investing.com
Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System – Company Announcement - Financial Times
Stryker Stock: Analyst Estimates & Ratings - Barchart.com
Breakthrough: FDA Approves Stryker's Revolutionary Nerve Ablation System for Chronic Back Pain Relief - Stock Titan
Stryker Inks Deal to Buy One of Its Suppliers Stryker Corp. will pay $150 million for Gaymar Indu - Medical Product Outsourcing
Boston Sci Closes Division Sale to Stryker Corp. On Jan. 3, Boston Scientific Corp. completed the - Medical Product Outsourcing
Stryker Moves to Settle DOJ Probe - Medical Product Outsourcing
Stryker’s Bone Growth Division Sold to Olympus Corp. Stryker Corp. has inked a deal to sell - Medical Product Outsourcing
Insulet Adds Stryker Executive to Board - Medical Product Outsourcing
Former Stryker CEO Receives Lifetime Achievement Award from AdvaMed - Medical Product Outsourcing
Stryker Settles for $80 Million in Unapproved Device Sales Case - Medical Product Outsourcing
Stryker Snaps Up Concentric for $135M - Medical Product Outsourcing
First-Quarter Sales Strong at Stryker Corp. - Medical Product Outsourcing
Stryker: We’re Not Buying Smith & Nephew … Yet, But We’re Interested - Medical Product Outsourcing
SYK Q1 Earnings Call: Stryker Delivers Revenue Beat, Cites International Growth and Tariff Headwinds - Yahoo Finance
Top Executive Sells Stryker Shares in Major Transaction - TipRanks
Stryker Corp Shareholders Approve Incentive Plans By Investing.com - Investing.com India
Stryker Corporation (SYK) Shareholders Approve Key Incentive Pla - GuruFocus
Stryker at Bank of America 2025 Healthcare Conference: Strategic Growth and Innovation - Investing.com
Stryker Corp Shareholders Approve Incentive Plans - Investing.com
There May Be Reason For Hope In Stryker's (NYSE:SYK) Disappointing Earnings - Yahoo Finance
스트라이커 (SYK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.72%
0.51%
자본화:
|
볼륨(24시간):